Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns

How does maternal vaccination with the respiratory syncytial virus prefusion F protein (RSVpreF) vaccine compare with passive infant immunization with nirsevimab for the prevention of RSV-related hospitalization?In this French nationwide study, infant immunization with nirsevimab was associated with a lower risk of RSV-related hospitalization compared with maternal vaccination with the RSVpreF vaccine (hazard ratio, 0.74). The risk of severe outcomes, including admission to the pediatric intensive care unit and requiring ventilator support or oxygen therapy, was also lower.Compared with maternal vaccination with the RSVpreF vaccine during the first RSV season in France, infant immunization with nirsevimab was associated with a lower risk of RSV-related hospitalization.

Corresponding Author: Marie-Joelle Jabagi, PharmD, PhD, French National Agency for Medicines and Health Products Safety, 143-147 Boulevard Anatole France, Saint-Denis CEDEX F-93285, France (marie-joelle.jabagi@ansm.sante.fr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.